Citi analyst Joanne Wuensch maintains $Edwards Lifesciences (EW.US)$ with a buy rating, and adjusts the target price from $83 to $77.
According to TipRanks data, the analyst has a success rate of 64.0% and a total average return of 6.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Edwards Lifesciences (EW.US)$'s main analysts recently are as follows:
The analyst expresses uncertainty regarding the sustainability of the recent surge in medical technology stocks as the industry approaches the third-quarter financial disclosures. A cautious stance is adopted entering the earnings season, with the third quarter traditionally posing as the most challenging period for the MedTech sector due to the focus on the 2025 outlook and the potential influence of projections for the upcoming year on short-term stock performance.
The expectation for MedTech is a continued positive utilization trend into Q3, with a 'healthy' capital expenditure outlook anticipated for the following year. Meanwhile, in life science tools, bioprocess trends are expected to show improvement in the second half. However, there is ongoing discussion regarding the outlook for instruments and the impact of China's stimulus, especially considering the recent performance of stocks in this sector.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
花旗分析師Joanne Wuensch維持$愛德華生命科學 (EW.US)$買入評級，並將目標價從83美元下調至77美元。
根據TipRanks數據顯示，該分析師近一年總勝率為64.0%，總平均回報率為6.4%。
此外，綜合報道，$愛德華生命科學 (EW.US)$近期主要分析師觀點如下：
隨着該行業接近第三季度財務披露，該分析師對最近醫療科技股飆升的可持續性表示不確定性。進入業績期時採取了謹慎的立場，由於關注2025年的前景以及來年的預測對短期股票表現的潛在影響，第三季度傳統上是醫療科技行業最具挑戰性的時期。
對MedTech的預期是，第三季度將持續保持積極的利用率，預計來年的資本支出前景將是 「健康」 的。同時，在生命科學工具方面，生物工藝趨勢預計將在下半年顯示出改善。但是，關於工具前景和中國刺激措施影響的討論仍在繼續，特別是考慮到該行業股票的近期表現。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
